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Oral manifestations in human 
immunodefi ciency virus infected 
pediatric patients receiving and 
not receiving antiretroviral therapy: 
a cross sectional study
Darshan Devang Divakar1, Abdulaziz Abdullah Al Kheraif1, Ravikumar Ramakrishnaiah1, 
Aftab Ahmed Khan1, Sandeepa NC2, Obaid Abdullah Alshahrani3, Ali Alahmari4
The aim of the study was to assess and compare oral manifestations of human immunodefi ciency virus (HIV) infected pediatric 
patients undergoing antiretroviral therapy (ART) and those not undergoing ART. A cross sectional study included HIV positive chil-
dren (receiving and not receiving ART) aged 5-15 years, registered at the District Hospital ART Centre, Udaipur, and HIV negative 
schoolchildren. HIV related oral lesions were diagnosed according to the World Health Organization criteria. Sociodemographic and 
other related information were  also recorded. CD4+ cell count was determined in all study subjects. The χ2-test, stepwise multiple 
linear regression and logistic regression were used on statistical analysis. In all tests, confi dence interval and p-value were set at 95% 
and ≤0.05, respectively. A greater proportion of HIV patients receiving treatment had CD4+ cell count of more than 750 cells/mm3. 
The majority of HIV patients receiving ART for more than three  years and only 20% of those not receiving ART were free from any oral 
lesions. The results of the present study demonstrated ART to be eff ective in reducing the prevalence of HIV related oral lesions, as 
already described in the literature; however, unlike previous studies, the present paper reports more valid fi ndings for having included 
most of the confounding variables.
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INTRODUCTION
The human immunodefi ciency virus/acquired immunode-
fi ciency syndrome (HIV/AIDS) epidemic is one of the most 
serious health hazards to aff ect humanity and the fastest 
growing threat to humanity today. It remains one of the 
world’s most signifi cant public health challenges, particu-
larly in low- and middle-income countries. According to the 
Global Health Observatory data Repository, 35 million peo-
ple were living with HIV worldwide at the end of 2013, with 
a mortality of 1.5 million (1).
The fi rst symptoms in HIV infected children are oral lesions 
which have been associated with immune suppression and 
reduced amounts of serum CD4+ T lymphocytes (2). In chil-
dren, oral lesions are associated with HIV infection and dis-
ease progression due to their opportunistic nature and are 
therefore part of the World Health Organization (WHO) clas-
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sifi cation to determine the clinical stage of pediatric HIV dis-
ease (3). When HIV status is not known, the lesions provide 
strong indication of the presence of HIV infection. For this 
reason, the presence and development of oral lesions are 
used as entry criteria and end points for prophylaxis and 
therapy, which explains the weight given to these lesions in 
HIV prevention and intervention programs (4). The use of 
new antiretroviral drugs, especially protease inhibitors, has 
markedly reduced mortality and increased life expectancy 
in the population infected by HIV. From 1996 till 2012, 
antiretroviral therapy (ART) averted 6.6 million AIDS-relat-
ed deaths worldwide, including 5.5 million deaths in low- 
and middle-income countries. As of December 2012, over 
900 000 pregnant women living with HIV globally received 
antiretroviral prophylaxis or treatment. Coverage of antiret-
roviral programs for the prevention of mother-to-child 
transmission (excluding the less eff ective single dose nevi-
rapine regimen) increased from 57% (51%-64%) in 2011 to 
62% (57%-70%) in 2012. From 2001 till 2012, there was a 
52% decline in new HIV infections among children (5). Re-
cent studies on ART from developed countries have con-
fi rmed reduction in the prevalence of oral lesions among 
infected adults and children (6, 7). Furthermore, in a recent 
Brazilian study on HIV-infected children, oral manifestations 
have been reported to be clinical predictors of highly active 
ART (HAART) failure (7). However, most of the studies inves-
tigating oral manifestations of HIV have been performed in 
western countries. Also, there is a dearth of information on 
patients on ART treatment and those not receiving treat-
ment. Therefore, the present study was conducted to assess 
and compare oral manifestations in HIV infected pediatric 
patients undergoing ART and those not undergoing ART.
MATERIALS AND METHODS
Study design, study population and study area
A descriptive cross sectional study included HIV positive 
children (receiving and not receiving ART) aged 5-15 years, 
registered at the District Hospital ART Centre, Udaipur, (Ra-
jasthan), and HIV negative schoolchildren enrolled in a near-
by school.
Offi  cial Permission, Ethical clearance and informed consent
The study protocol was reviewed by the institutional Ethics 
Committee and was granted ethical clearance. Offi  cial per-
missions were obtained from the District Hospital Anti-Ret-
roviral Therapy Centre, Udaipur (Rajasthan) and the selected 
school. Parents of the selected children signed the written 
informed consent form.
Inclusion criteria
• For HIV positive subjects: subjects positive on particle 
 agglutination test for antibodies to HIV (Capillus® Trinity 
Biotech PLC, Bray, County Wicklow, Ireland) and enzyme-
linked immunosorbent assay (ELISA) (Enzygnost® Anti-
HIV 1/2 Plus, Behring, Behringwerke AG, Marburg, Ger-
many).
• For controls: systemically healthy subjects.
Exclusion criteria
Subjects with a history of adverse habits like tobacco, betel 
nut, etc.
Sample selection
Sixty-two HIV positive patients undergoing ART for at least a 
month and 55 patients not undergoing any treatment and 
fulfi lling the eligibility criteria were randomly selected from 
patients visiting District Hospital ART centre, Udaipur, from 
June 2014 to August 2014. Fifty control children of the same 
age group were randomly selected from a nearby school.
Proforma details
Study proforma consisted of three sections:
1.  General information: age, gender, place of residence (ur-
ban/rural), socioeconomic status, duration of HIV infec-
tion, duration of ART, use of traditional medicine, pres-
ence of HIV related systemic disease, and group of chil-
dren (I, II, III). Socioeconomic status was recorded 
according to Prasad’s classifi cation (8) of socioeconomic 
status scale based on which it was stratifi ed into 5 cate-
gories, viz. Upper High, High, Upper Middle, Lower Mid-
dle and Poor.
2.  Clinical examination:
  Oral manifestations: HIV related oral lesions were diag-
nosed according to the WHO criteria (9).
3. Biochemical investigations:
 CD4+ cell count.
Clinical examination was made according to Type III exami-
nation as described in the WHO Oral Health Survey Basic 
Methods, 1997 (10).
Infection control
For examination, well sterile and disposable ice-cream 
wooden sticks, mouth mirrors and explorers were used. All 
the universal precautions were followed.
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Statistical analysis
The recorded data were compiled and entered in a spread-
sheet computer program (Microsoft Excel 2007) and then 
exported to data editor page of the SPSS version 15 (SPSS 
Inc., Chicago, Illinois, USA). The χ2-test, stepwise multiple lin-
ear regression and multiple logistic regression were used on 
statistical analysis. In all tests, confi dence interval (CI) and 
the level of signifi cance were set at 95% and ≤0.05, respec-
tively.
RESULTS
Among all HIV positive subjects, 62 (34.7%) subjects were 
receiving ART and 55 (30.7%) subjects were not receiving 
ART. The majority of study subjects were in the age range of 
11-15 years (62%) and were males (56.9%). The majority of 
subjects receiving ART were urban residents and those not 
receiving ART were rural residents. Most of the HIV positive 
subjects were of lower socioeconomic background. How-
ever, the proportion of subjects of higher socioeconomic 
TABLE 1. Distribution of study subjects
Variable
HIV patients receiving ART







Short term therapy 
(<3 years)
Long term therapy 
(≥3 years)
Age (yrs)
5-10 13 (48.2) 15 (42.9) 19 (30) 25 (40.3) 72 (38)
11-15 14 (51.9) 20 (57.1) 36 (70) 37 (59.7) 107 (62)
Gender
Male 15 (55.6) 22 (62.9) 29 (50) 36 (58.1) 102 (56.9)
Female 12 (44.4) 13 (37.1) 26 (50) 26 (41.9) 77 (43)
Place of residence
Urban 17 (62.9) 21 (60) 27 (46) 29 (46.8) 94 (52.5)
Rural 10 (37.1) 14 (40) 28 (54) 33 (53.2) 85 (47.4)
Socioeconomic status
Upper high 2 (7.4) 2 (5.7) 0 5 (8.1) 9 (4)
High 3 (11.1) 3 (8.6) 0 2 (3.2) 8 (3.3)
Upper middle 5 (18.5) 5 (14.3) 7 (12.7) 15 (27.3) 32 (17.3)
Lower middle 10 (37) 13 (37.1) 23 (41.8) 13 (23.6) 59 (36)
Poor 7 (25.9) 12 (34.3) 25 (45.4) 27 (49.1) 71 (39.3)
Duration of HIV infection (yrs)
≤2 years 18 (66.7) 11 (25) 39 (70.9) - 68 (34)
>2 years 9 (33.3) 24 (75) 16 (29.1) - 49 (32.7)
Presence of HIV related systemic disease
Yes 16 (59.3) 15 (46.9) 43 (78.2) 0 74 (42)
No 11 (40.7) 20 (53.1) 12 (21.8) 62 (100) 105 (24.7)
Use of traditional medicine
Yes 15 (55.5) 15 (37.5) 35 (63.6) 0 65 (37.3)
No 12 (44.5) 20 (62.5) 20 (36.4) 62 (100) 114 (62.7)
CD4+ cell count (cell/mm3)
<250 8 (29.6) 3 (6.3) 27 (49.1) - 38 (22)
250-750 5 (18.5) 9 (21.9) 22 (40) - 36 (20.7)
>750 14 (51.9) 23 (71.9) 6 (10.9) - 43 (24)
Oral lesions
None 12 (44.5) 28 (80) 12 (21.8) 62 (100) 114 (72)
Linear gingival erythema 0 0 3 (5.5) 0 3 (1.3)
Hairy leukoplakia 0 0 3 (5.5) 0 3 (2)
Angular cheilitis 0 0 4 (7.3) 0 4 (1.3)
Oral ulcers 3 (11.1) 2 (5.7) 4 (7.3) 0 9 (4.7)
Candidiasis 10 (37) 1 (2.8) 21 (38.2) 0 32 (15.3)
Hyperpigmentation 2 (7.4) 4 (11.4) 8 (14.5) 0 14 (3.3)
Total 27 (15.1) 35 (19.6) 55 (30.7) 62 (34.6) 179 (100)
HIV = human immunodefi ciency virus; ART = antiretroviral therapy
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status was greater among those receiving ART than among 
those not receiving ART. Around 70% of those not receiving 
ART had HIV infection for less than two  years. The majority 
(63.6%) of subjects not receiving ART were on traditional 
medicine. Around half of the HIV positive subjects not re-
ceiving ART showed CD4+ cells count of less than 250 cells/
mm3, whereas the majority of subjects receiving ART had 
CD4+ cells count of more than 750 cells/mm3. Only 20% of 
HIV positive subjects receiving ART for more than three 
years had oral mucosal lesions. Among those not receiving 
ART, 78.2% of subjects had oral mucosal lesions (Table 1).
Bivariate analysis revealed signifi cant association of the pre-
sence of oral lesions with socioeconomic status (p=0.023), 
duration of HIV infection (p=0.05), presence of HIV related 
systemic disease (p=0.004), CD4+ cell count (p=0.044) and 
ART treatment (p=0.032) (Table 2). According to multivari-
ate modeling, the best predictor of the presence of oral le-
sions was the presence of HIV related systemic disease, fol-
lowed by ART therapy, with variances of 4.5% and 42.1%, 
respectively. Duration of HIV infection, CD4+ cell count and 
socioeconomic status also predicted the presence of oral 
lesions with the variances of 43.5%, 51.2% and 66.2%, re-
spectively (Table 3). Multiple logistic regression analysis de-
picted that patients not receiving ART had 5.634 (odds ra-
tio) (p≤0.05) times greater risk of developing oral lesions 
TABLE 4. Odds ratio (OR) and 95% confi dence interval (CI) for HIV 
related oral lesions according to multiple logistic regression
Independent variable HIV related oral lesionOR (95% CI)
Socioeconomic status: low/high 4.434* (2.361-13.521)
Duration of HIV infection: 
≤2 years/>2 years
0.671* (0.136-2.888)
Presence of HIV related systemic 
disease: yes/no
5.777* (1.654-5.892)
CD4+ cell count: ≤250/>250 1.999* (0.129-3.688)
Patient receiving ART therapy: 
not receiving ART/receiving ART
5.634* (2.341-9.888)
HIV = human immunodefi ciency virus; ART = antiretroviral therapy; 
*statistically signifi cant at p≤0.05
TABLE 3. Stepwise multiple linear regression analysis with HIV related 
oral lesion as dependent variable
Model R R2 F- value p-value
HIV related oral lesion
1 0.134a 0.045 129.12 0.000a
2 0.812b 0.421 136.77 0.000b
3 0.914c 0.435 99.56 0.000c
4 0.856d 0.512 97.812 0.000d
5 0.843e 0.662 94.333 0.000e
a.  Predictors: (Constant), Presence of systemic disease.
b.  Predictors: (Constant), Presence of systemic disease, 
not receiving ART therapy.
c.  Predictors: (Constant), Presence of systemic disease, 
not receiving ART therapy, Duration of HIV infection.
d.  Predictors: (Constant), Presence of systemic disease, 
not receiving ART therapy, Duration of HIV infection, CD4+ cell count.
e.  Predictors: (Constant), Presence of systemic disease, 
not receiving ART therapy, Duration of HIV infection, CD4+ cell count, 
socioeconomic status.
HIV = human immunodefi ciency virus; ART = antiretroviral therapy
TABLE 2. Prevalence of HIV related oral lesions among HIV positive 
subjects
Variable




5-10 years (n=47) 17 (36.2) 30 (63.8)
0.68
10-15 years (n=70) 35 (50) 35 (50)
Gender
Male (n=55) 20 (36.4) 35 (63.6)
0.54
Female (n=62) 32 (51.6) 30 (48.4)
Place of residence
Urban (n=65) 19 (29.2) 38 (58.5)
0.11
Rural (n=52) 33 (63.5) 27 (51.9)
Socioeconomic status
Upper high (n=4) 1 (25) 3 (75)
0.023*
High (n=6) 2 (33.3) 4 (66.7)
Upper middle (n=17) 5 (29.4) 12 (70.6)
Lower middle (n=46) 21 (45.7) 25 (54.3)
Poor (n=44) 23 (52.3) 21 (47.7)
Duration of HIV infection (yrs)
≤2 years (n=68) 23 (33.8) 45 (66.2)
0.05*
>2 years (n=49) 29 (59.2) 20 (40.8)
Presence of HIV related systemic disease
Yes (n=74) 39 (52.7) 35 (47.3)
0.004*
No (n=43) 13 (30.2) 30 (69.7)
Use of traditional medicine
Yes (n=65) 21 (32.3) 44 (67.8)
0.89
No (n=52) 31 (59.6) 21 (40.4)
CD4+ cell count (cell/mm3)
<250 (n=38) 25 (65.8) 13 (34.2)
0.044*250-750 (n=36) 19 (52.8) 17 (47.2)
>750 (n=43) 8 (18.6) 35 (81.4)
HIV positive subjects
On ART (n=62)
<3 years (n=27) 15 (55.5) 12 (44.4)
0.032*
≥3 years (n=35) 7 (20) 28 (80)
Not on ART (n=55) 43 (78.2) 12 (21.8)
Total (n=117) 52 (44.5) 65 (55.5)
HIV = human immunodefi ciency virus; ART = antiretroviral therapy; test 
applied: χ2-test; *statistically signifi cant diff erence at p≤0.05
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than those receiving ART. Table 4 shows the signifi cant odds 
ratios of 3.51, 0.512, 2.789, 1.916 and 5.27 for socioeconomic 
status, duration of HIV infection, presence of HIV related sys-
temic disease, CD4+ cell count and group (ART treatment), 
respectively.
DISCUSSION
Oral manifestations are observed commonly in adults and 
children with HIV infection (11,12). ART is known to suppress 
HIV replication and helps in immune reconstitution in HIV 
patients. An association between oral mucosal lesions and 
immunosuppression has already been documented (13, 
14). Hence, this study compared the HIV related oral lesions 
in patients undergoing ART and those not taking any treat-
ment.
In the present study, candidiasis was evidenced to be the 
fi rst most common oral lesion, followed by oral ulcers and 
mucosal hyperpigmentation. A similar prevalence of can-
didiasis and oral ulcer was observed by Leggott (1992) (15) 
(13%) and Alexio et al. (2010) (16) (4%). Oral candidiasis has 
also been reported as the most common oral lesion among 
HIV infected subjects in Thailand (17). Among South African 
pediatric patients, oral candidiasis was most common, fol-
lowed by oral ulcers (18). Oral lesions may have negative 
impact on the nutritional health of the children by reducing 
food intake as a result of discomfort during eating (14). In 
another review of published reports, Enwonwu (19) revealed 
that malnutrition may induce mucosal disruptions predis-
posing candidiasis. The prevalence of mucosal hyperpig-
mentation in the present study was consistent with the 
fi ndings reported by Hamza et al. (2006) (20), which might 
be attributed to the increased melanin production in the 
epithelium associated with the increased release of alpha-
melanocyte-stimulating hormone (α-MSH) (21).
The presence of systemic disease was found to be the best 
predictor of oral lesions in the present study. Similar associa-
tion has also been reported by Ranganathan et al. (2010) 
among pediatric HIV patients from South India (22, 17). The 
presence of oral lesions has signifi cant eff ects on the health 
related quality of life in HIV patients. Dysphagia caused by 
oral lesions might cause malnutrition and continuous clini-
cal deterioration (4).
In the present study, oral lesions showed greater prevalence 
in the lower socioeconomic group subjects as compared to 
the upper socioeconomic group subjects. Noce (2009) re-
viewed the association between socioeconomic status and 
HIV-associated oral lesions in Rio de Janeiro from 1997 to 
2004 and concluded that socioeconomic status was associ-
ated with immunosuppression and prevalence of oral le-
sions (23). In confi rmation to previous research, duration of 
HIV infection was also observed as one of the predictors of 
oral lesions among HIV patients in the present study, indi-
cating that worsening in the prevalence of oral lesions also 
varied signifi cantly with the increasing duration of HIV in-
fection, which is consistent with a previous study (24).
The patients on ART had a signifi cantly increased CD4 cell 
count as compared to those not receiving ART in the pre-
sent study. Moreover, those on long term therapy (>3 years) 
had better immunosuppression in terms of CD4 cell count 
than those on short term therapy. Retrospective review of 
electronically captured data from patients initiating HAART 
at a south-eastern US clinic elicited signifi cant association of 
CD4+ cell count and presence of oral lesions (25). Petruzzi et 
al. (2013) (26) also report similar fi ndings among south Bra-
zilian patients. Gullick et al. (1997) (27) and Pakkar et al. (1998) 
(28) report that the gradual CD4 cell count rise is likely to 
refl ect the generation of new cells by peripheral expansion 
of pre-existing T cell clones or generation of thymically de-
rived naïve cells in ART patients.
The use of traditional medicine did not show any associa-
tion with the presence of oral lesions in the present study, 
an observation that is in agreement with that reported ear-
lier in Tanzania (29). It is crucial to learn more about the na-
ture and composition of these plant medicines and their 
potential interactions with drugs that are used for the man-
agement of HIV/AIDS and its associated opportunistic dis-
eases.
In confi rmation of the fi ndings reported by Tappuni and 
Fleming (11) and Pinheiro et al. (2009) (30), the present study 
revealed signifi cantly fewer HIV-related oral manifestations 
among patients receiving ART (35.4%) than in the non-ART 
group (78.2%). This might be an expression of reconstituted 
immune system as a result of ART. However, on the other 
hand, some authors (30) found an increase in salivary gland 
disease and a striking increase in oral warts in some pa-
tients, probably as a complication of ART. No such adverse 
eff ects were observed in the present study.
Notably, in the present study, the patients on ART for more 
than three  years had a signifi cantly lower prevalence of oral 
lesions than those on long term therapy, which corrobo-
rates the fi ndings of a previous study (31).
As this was an institutional study including a single institu-
tion, all HIV patients on standardized triple drug regimens 
were included in the present study, thus ensuring removal 
of the confounding eff ect of diff erent drug regimens. The 
confounding eff ect of other variables was taken in consid-
eration through mathematical modeling, which was defi -
cient in previous researches. Quality-assured laboratory as-
says were performed in a single nationally accredited labo-
ratory. The cross sectional nature of the present study 
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limited the validity of the study to a certain extent, enhanc-
ing the need of future longitudinal studies on the same is-
sue. Besides, further studies are necessary to access the HIV-
infected children groups using other combinations of ART. 
CONCLUSION
Reduction in oral lesions among AIDS patients on ART was 
clearly demonstrated in the present study. Our study propos-
es that oral lesions may be considered as clinical markers of 
virologic failure in HIV-infected patients receiving ART. Hence, 
there is a need to centralize research eff orts in poor countries 
to support standardized studies in order to explore the use of 
oral lesions as surrogate markers for the initiation of ART and 
prophylaxis of opportunistic diseases. There is also a need to 
integrate oral health care into the general medical care of 
these children to ensure regular screening for oral lesions and 
appropriate early management.
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S A Ž E T A K
Oralne manifestacije u pedijatrijskih bolesnika zaraženih 
virusom humane imunodefi cijencije na antiretrovirusnoj 
terapiji i bez nje: presječno istraživanje
Darshan Devang Divakar, Abdulaziz Abdullah Al Kheraif, Ravikumar Ramakrishnaiah, Aftab Ahmed Khan, 
Sandeepa NC, Obaid Abdullah Alshahrani, Ali Alahmari
Cilj istraživanja bio je procijeniti i usporediti oralne manifestacije u pedijatrijskih bolesnika zaraženih virusom humane imunodefi -
cijencije (HIV) koji primaju antiretrovirusnu terapiju (ART) i onih koji ne primaju ovu terapiju. Ovo presječno istraživanje uključilo je 
HIV pozitivnu djecu (djecu koja primaju ART i djecu koja ne primaju ART) u dobi od 5-15 godina, registriranu pri Centru za ART u 
Pokrajinskoj bolnici u Udaipuru te HIV negativnu školsku djecu. Oralne promjene povezane s HIV-om dijagnosticirane su prema kri-
terijima Svjetske zdravstvene organizacije. Prikupljeni su socio-demografski te ostali podaci za svu djecu uključenu u ispitivanje. U 
svih je određen broj CD4+ stanica. U statističkoj analizi primijenjen je χ2-test te postupna višestruka linearna regresija i logistička re-
gresija. U svim testovima interval vjerodostojnosti i vrijednost p utvrđeni su na razini od 95% odnosno ≤0,05. Broj CD4+ stanica veći 
od 750 stanica/mm3 zabilježen je u većem postotku HIV bolesnika na ART. Bez oralnih promjena bila je većina HIV bolesnika koji su 
primali ART duže od tri  godine, ali samo 20% onih koji nisu primali ART. Rezultati ovoga istraživanja pokazuju da ART učinkovito 
snižava učestalost oralnih promjena povezanih s HIV-om, što je već prije opisano u literaturi. Međutim, za razliku od prijašnjih ispiti-
vanja, nalazi prikazani u ovom radu imaju veću vrijednost, jer uključuju većinu čimbenika  koji  bi  mogli  utjecati  na  rezultate.
Ključne riječi: antiretrovirusna terapija, visoko aktivna; virus humane imunodefi cijencije; oralne manifestacije
